G
Gustavo Lopardo
Publications - 4
Citations - 2309
Gustavo Lopardo is an academic researcher. The author has contributed to research in topics: Public health & Disease burden. The author has an hindex of 2, co-authored 4 publications receiving 1283 citations.
Papers
More filters
Journal ArticleDOI
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Hongchao Pan,Richard Peto,Ana-Maria Henao-Restrepo,Marie-Pierre Preziosi,Vasee Sathiyamoorthy,Quarraisha Abdool Karim,Marissa M. Alejandria,César Hernández García,Marie-Paule Kieny,Reza Malekzadeh,Srinivas Murthy,K. Srinath Reddy,Mirta Roses Periago,Pierre Abi Hanna,Florence Ader,Abdullah M. Al-Bader,Almonther Alhasawi,Emma Allum,Athari Alotaibi,Carlos A Alvarez-Moreno,Sheila Appadoo,Abdullah Asiri,Pål Aukrust,Andreas Barratt-Due,Samir Bellani,Mattia Branca,Heike B. C. Cappel-Porter,Nery Cerrato,Ting S. Chow,Najada Como,Joseph A. Eustace,Patricia J. Garcia,Sheela Godbole,Eduardo Gotuzzo,Laimonas Griskevicius,Rasha Hamra,Mariam Hassan,Mohamed Hassany,David Hutton,Irmansyah Irmansyah,Ligita Jancoriene,Jana Kirwan,Suresh Kumar,Peter Lennon,Gustavo Lopardo,Patrick Lydon,Nicola Magrini,Teresa Maguire,Suzana Manevska,Oriol Manuel,Sibylle McGinty,Marco T. Medina,María L. Mesa Rubio,Maria C. Miranda-Montoya,Jeremy Nel,Estevão Portela Nunes,Markus Perola,Antonio Portolés,Menaldi R. Rasmin,Aun Raza,Helen Rees,Paula P. S. Reges,Chris A Rogers,Kolawole Salami,Marina I. Salvadori,Narvina Sinani,Jonathan A C Sterne,Milena Stevanovikj,Evelina Tacconelli,Kari A.O. Tikkinen,Sven Trelle,Hala Zaid,John-Arne Røttingen,Soumya Swaminathan +73 more
TL;DR: These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.
Posted ContentDOI
Repurposed antiviral drugs for COVID-19: interim WHO solidarity trial results (Preprint)
Pan Hongchao,Richard Peto,Ana-Maria Henao-Restrepo,Marie-Pierre Preziosi,Vasee Sathiyamoorthy,Quarraisha Abdool Karim,Marissa M. Alejandria,César Hernández García,Marie-Paule Kieny,Reza Malekzadeh,Srinivas Murthy,K. Srinath Reddy,Mirta Roses Periago,Pierre Abi Hanna,Florence Ader,Abdullah M. Al-Bader,Almonther Alhasawi,Emma Allum,Athari Alotaibi,Carlos Alvarez-Moreno,Sheila Appadoo,Abdullah Asiri,Pål Aukrust,Andreas Barratt-Due,Samir Bellani,Mattia Branca,Heike B. C. Cappel-Porter,Nery Cerrato,Ting S. Chow,Najada Como,Joseph A. Eustace,Patricia J. Garcia,Sheela Godbole,Eduardo Gotuzzo,Laimonas Griskevicius,Rasha Hamra,Mariam Hassan,Mohamed Hassany,David W. Hutton,Irmansyah Irmansyah,Ligita Jancoriene,Jana Kirwan,Suresh Kumar,Peter Lennon,Gustavo Lopardo,Patrick Lydon,Nicola Magrini,Teresa Maguire,Suzana Manevska,Oriol Manuel,Sibylle McGinty,Marco T. Medina,María L. Mesa Rubio,Maria C. Miranda-Montoya,Jeremy Nel,Estevão Portela Nunes,Markus Perola,Antonio Portolés,Menaldi R. Rasmin,Aun Raza,Helen Rees,Paula P. S. Reges,Chris A Rogers,Kolawole Salami,Marina I. Salvadori,Narvina Sinani,Jonathan A C Sterne,Milena Stevanovikj,Evelina Tacconelli,Kari A.O. Tikkinen,Sven Trelle,Hala Zaid,John-Arne Røttingen,Soumya Swaminathan,Múltipla ver em Notas +74 more
TL;DR: These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.
Journal ArticleDOI
Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis.
Charles Whittaker,Oliver J Watson,Carlos Alvarez-Moreno,Nasikarn Angkasekwinai,Adhiratha Boonyasiri,Luis Carlos Triana,Duncan Chanda,Lantharita Charoenpong,Methee Chayakulkeeree,Graham S Cooke,Julio Croda,Julio Croda,Zulma M. Cucunubá,Zulma M. Cucunubá,Bimandra A Djaafara,Cássia Fernanda Estofolete,Maria Eugenia Grillet,Nuno R. Faria,Nuno R. Faria,Nuno R. Faria,Silvia Figueiredo Costa,David A Forero-Peña,Diana M. Gibb,Anthony C. Gordon,Raph L. Hamers,Arran Hamlet,Vera Irawany,Anupop Jitmuang,Nukool Keurueangkul,Teresia Njoki Kimani,Margarita Lampo,Anna S. Levin,Gustavo Lopardo,Rima Mustafa,Shevanthi Nayagam,Thundon Ngamprasertchai,Ng’ang’a Irene Hannah Njeri,Maurício Lacerda Nogueira,Esteban Ortiz-Prado,Mauricio W. Perroud,Andrew N. Phillips,Panuwat Promsin,Ambar Qavi,Alison Rodger,Ester Cerdeira Sabino,Sorawat Sangkaew,Djayanti Sari,Rujipas Sirijatuphat,Andrei C. Sposito,Pratthana Srisangthong,Hayley A Thompson,Zarir F Udwadia,Sandra Valderrama-Beltrán,Peter Winskill,Azra C. Ghani,Patrick G T Walker,Timothy B. Hallett +56 more
TL;DR: In this paper, the authors explore the public health impact of different potential therapeutics, under a range of scenarios varying healthcare capacity, epidemic trajectories; and drug efficacy in the absence of supportive care.
Posted ContentDOI
Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis
Charles Whittaker,Oliver J Watson,Carlos Alvarez-Moreno,Nasikarn Angkasekwinai,Adhiratha Boonyasiri,Luis Carlos-Triana,Duncan Chanda,Lantharita Charoenpong,Methee Chayakulkeeree,Graham S Cooke,Julio Croda,Zulma Cucunuba,Bimandra A. Djafaara,Cássia Fernanda Estofolete,Maria Eugenia-Grillet,Nuno R. Faria,Silva Figueiredo-Costa,David A Forero-Peña,Diana M. Gibb,Anthony C. Gordon,Raph L. Hamers,Arran Hamlet,Vera Irawany,Anupop Jitmuang,Nukool Keurueangkul,Teresia Njoki Kimani,Margarita Lampo,Anna S. Levin,Gustavo Lopardo,Rima Mustafa,Shevanthi Nayagam,Thundon Ngamprasertchai,Ng’ang’a Irene Hannah Njeri,Maurício Lacerda Nogueira,Esteban Ortiz-Prado,Mauricio W. Perroud,Andrew N. Phillips,Panuwat Promsin,Ambar Qavi,Alison Rodger,Ester Cerdeira Sabino,Sorawat Sangkaew,Djayanti Sari,Rujipas Sirijatuphat,Andrei C. Sposito,Pratthana Srisangthong,Hayley A Thompson,Zarir Udwadia,Sandra Valderrama-Beltrán,Peter Winskill,Azra C. Ghani,Patrick G T Walker,Timothy B. Hallett +52 more
TL;DR: In this paper, the authors developed a mathematical model of SARS-CoV-2 transmission, COVID-19 disease and clinical care to explore the potential public-health impact of a range of different potential therapeutics, under different scenarios varying: i) healthcare capacity, ii) epidemic trajectories; and iii) drug efficacy in the absence of supportive care.